Mural Oncology (NASDAQ:MURA – Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($2.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.96) by ($0.05), RTT News reports. During the same period in the prior year, the company posted ($3.57) EPS.
Mural Oncology Trading Down 1.8 %
Mural Oncology stock opened at $3.73 on Thursday. The stock has a market cap of $63.48 million, a price-to-earnings ratio of -0.41 and a beta of 3.66. The company’s 50-day moving average price is $3.84 and its two-hundred day moving average price is $3.58. Mural Oncology has a 52 week low of $2.87 and a 52 week high of $5.38.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Mural Oncology in a report on Wednesday.
About Mural Oncology
Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.
Read More
- Five stocks we like better than Mural Oncology
- Should You Invest in Penny Stocks?
- Nu Holdings: Is Brazil’s Fintech Leader a Buy at This Discount?
- What does consumer price index measure?
- 3 Magnificent 7 Stocks Trading Near 50-Day Lows—Time to Buy?
- How to Find Undervalued Stocks
- 3 Stocks With Ironclad Balance Sheets for Long-Term Stability
Receive News & Ratings for Mural Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mural Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
